Promega announced today that it will develop its microsatellite instability (MSI) technology for Merck.

According to a release, MSI technology may be used to better characterize tumors and guide therapeutic choices for MSI-High cancer types. Promega and Merck will initially seek regulatory approval in the United States and China, with additional territories a possibility.

“It is gratifying to see our MSI technology have such meaning within the oncology community,” Promega President and CEO Bill Linton said in a statement. “Promega developed this technology well over a decade ago and our long-term commitment to R&D helped evolve its use.”

Financial terms were not disclosed.

Promega also announced that it intends to seek regulatory clearance for an MSI in vitro diagnostic (IVD) test in the United States, China and Europe.